“This newly available treatment may help reduce the risk of disease recurrence, progression and death in resectable NSCLC when given before surgery," said Dr Meredith Edwards, the medical director of Bristol Myers Squibb Australia. …
First immunotherapy-based neoadjuvant treatment for resectable NSCLC now funded via the PBS
August 1, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Week in Review' - 24 January
January 24, 2025 - - Podcast -
Cabinet documents reveal decades-old focus on faster PBS listings
January 24, 2025 - - Latest News -
No probity advisor but what about a form of confidentiality deed?
January 24, 2025 - - Latest News -
CEPI backing for Vaxxas to advance needle-free thermostable mRNA vaccines
January 23, 2025 - - Latest News -
New preventive treatments could support ongoing fight against COVID
January 23, 2025 - - Latest News -
Pharmac encourages input on on multiple medicines funding proposal
January 22, 2025 - - Latest News -
Immutep completes patient enrolment for EFTISARC-NEO Phase 2 trial
January 22, 2025 - - Australian Biotech